Comparing one vs. multiple anti-VEGF shots in diabetic cataract surgery
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether getting one injection of an anti-VEGF drug before cataract surgery works as well as getting several injections. It is for diabetic patients with mild to moderate diabetic eye disease who are having cataract surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older
- You have diabetes and non-proliferative diabetic retinopathy
- You need cataract surgery
- You do not have severe diabetic eye disease (like proliferative retinopathy or macular edema affecting the center of vision)
- You have not had eye surgery, laser, or anti-VEGF injections in the study eye within the past 6 months
- Your overall health is stable (no recent stroke or heart attack)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests if combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than aflibercept alone for people with diabetic macular edema caused by inflammation. It aims to find the best first treatment for improving vision and reducing swelling.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This trial tests a higher dose of aflibercept (8 mg) for people whose diabetic macular edema, retinal vein occlusion, or myopic choroidal neovascularization has not improved with standard treatment. The goal is to see if this stronger dose can reduce fluid and improve vision.
Hear when a new Cataract trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.